Biotech
Annexon Biosciences
Annexon Biosciences raises $125M Series D at $750M valuation
$125M
Total Raised
Series D
Latest Round
2011
Founded
150+
Employees
180 Kimball Way, South San Francisco, CA 94080
1 min read
Quick Facts
Valuation
$750M
Latest Round Size
$125M
Latest Round Date
August 2024
Annexon Biosciences: Series D Funding Round
Annexon Biosciences has successfully raised $125M in Series D funding, reaching a valuation of $750M.
Company Overview
Classical complement pathway inhibitors
Funding Details
The Series D round was led by GV, with participation from Alta Partners, Omega Funds, Cowen Healthcare Investments, Redmile Group.
Company Information
- Headquarters: 180 Kimball Way, South San Francisco, CA 94080
- Founded: 2011
- Employees: 150+
- Category: Biotech
Investment
Annexon Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series D
- Alta Partners: Verified investor in Series D
- Omega Funds: Verified investor in Series D
- Cowen Healthcare Investments: Verified investor in Series D
- Redmile Group: Verified investor in Series D
Key Investors
GV
Lead Investor
Verified investor in Series D
Alta Partners
Investor
Verified investor in Series D
Omega Funds
Investor
Verified investor in Series D
Cowen Healthcare Investments
Investor
Verified investor in Series D
Redmile Group
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M